2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Alexander M. Lesokhin, MD, discusses the utility of elranatamab in the ongoing phase 2 MagnetisimMM-3 trial in relapsed/refractory multiple myeloma.
Alexander M. Lesokhin, MD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the utility of elranatamab (PF-06863135) in the ongoing phase 2 MagnetisimMM-3 trial (NCT04649359) in relapsed/refractory multiple myeloma.
Elranatamab is a BCMA-directed bispecific antibody that binds to specific moieties: BCMA on the myeloma cells and CD-3 on immune cells, Lesokhin says. The agent elicits a cell-killing effect by activating the T-cells in the vicinity of the myeloma cells.
Subcutaneously administered elranatamab was evaluated in the phase 1 dose-escalation MagnetisMM-1 trial (NCT03269136). The results of the trial demonstrated efficacy with a 215 µg/kg dose of the bispecific antibody in patients with relapsed/refractory multiple myeloma. Moreover, an overall response rate of 70% was observed among 20 patients who received at least 215 μg/kg of elranatamab, Lesokhin notes.
Moreover, among patients treated above the dose threshold, 4 received prior BCMA-directed therapy, including CAR T-cell therapy or an antibody-drug conjugate. Of those patients, 3 responded to elranatamab, suggesting that sequential administration of BCMA-directed therapies is a potential treatment strategy that can be employed in this patient population, Lesokhin concludes.